{
  "id": 4675194,
  "title": "Sustained reductions in inflammatory markers seen with novel antibody drug",
  "url": "https://urgent.news/2026/08/31/sustained-reductions-in-inflammatory-markers-seen-with-novel-antibody",
  "topic": "culture",
  "section": "Culture",
  "published": "2026-08-31T16:20:09.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-08-sustained-reductions-inflammatory-markers-antibody.html"
  },
  "original_language": "en",
  "account": null,
  "summary": "The interleukin-6 (IL-6) antibody pacibekitug produced sustained reductions in inflammatory biomarkers in patients with chronic kidney disease at high inflammatory risk, according to results from the Phase II TRANQUILITY trial presented in a Hot Line session at ESC Congress 2026.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}